ImmunoPrecise Antibodies' subsidiary, BioStrand, launches AI-driven drug discovery tool LENSai API software.
ImmunoPrecise Antibodies' subsidiary, BioStrand, has launched the commercial version of LENSai API software, an AI-driven drug discovery tool. The subscription-based software combines BioStrand's LENSai technology with electronic health records, allowing users to access and merge data for drug generation analysis. The full LENSai data management platform is scheduled for release in Q1/Q2 2025.
June 10, 2024
5 Articles